Bionano Genomics Files 8-K on Financials

TL;DR

BNGO dropped an 8-K detailing financials - check it out.

AI Summary

Bionano Genomics, Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing details the company's operational and financial status as of the reporting date.

Why It Matters

This filing provides crucial updates on Bionano Genomics' financial health and operational performance, which are key indicators for investors and stakeholders.

Risk Assessment

Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful review.

Key Players & Entities

• Bionano Genomics, Inc. (company) — Registrant
• November 13, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• San Diego, California (location) — Principal Executive Office

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share BNGO The Nasdaq Sto

Filing Documents

• bngo-20241113.htm (8-K) — 31KB
• a2024-09x30bngox3qearnings.htm (EX-99.1) — 214KB
• picture3a.jpg (GRAPHIC) — 3KB
• picture4a.jpg (GRAPHIC) — 2KB
• 0001411690-24-000060.txt ( ) — 394KB
• bngo-20241113.xsd (EX-101.SCH) — 2KB
• bngo-20241113_lab.xml (EX-101.LAB) — 21KB
• bngo-20241113_pre.xml (EX-101.PRE) — 12KB
• bngo-20241113_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On November 13, 2024 , Bionano Genomics, Inc. (the "Company") issued a press release reporting its financial results for the third quarter ended September 30, 2024. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated into this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "estimate," "expect," "may," "plan," "will," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our expectations regarding product uptake, revenue growth, market development and OGM adoption, including through publications highlighting the utility and applications of OGM; our growth prospects and future financial and operating results; the growth of our installed OGM system base; the sale of our flowcell consumables and the other expectations related thereto; our commercial expectations; the anticipated benefits and success of our collaboration efforts; continued research, presentations and publications involving OGM and its utility compared to traditional cytogenetics and our technologies; our ability to drive adoption of OGM and our technology solutions; any potential proceeds from the exercise of the Series A, Series B, Series C and Series D warrants; our plans to hold a special meeting of stockholders; our cost savings and strategic productivity initiatives; our expectation of a reduction in non-cash charges in the future; and efforts to extend our cash runway. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the timing and amount of revenue we are able to recognize in a given fiscal peri

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued November 13, 2024, reporting financial results for the third quarter ended September 30, 2024 104 Inline XBRL for the cover page of this Current Report on Form 8-K

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Bionano Genomics, Inc. Date: November 13, 2024 By: /s/ R. Erik Holmlin, Ph.D. R. Erik Holmlin, Ph.D. President and Chief Executive Officer (Principal Executive and Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR